Dual inhibition of key proliferation signaling pathways in triple-negative breast cancer cells by a novel derivative of Taiwanin A

Yueh Hsiung Kuo, En Pei Isabel Chiang, Che Yi Chao, Raymond L. Rodriguez, Pei Yu Chou, Shu Yao Tsai, Man Hui Pai, Feng Yao Tang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The treatment of breast cancer cells obtained by blocking the aberrant activation of the proliferation signaling pathways PI3K/Akt/mTOR and MEK/ERK has received considerable attention in recent years. Previous studies showed that Taiwanin A inhibited the proliferation of several types of cancer cells. In this study, we report that 3,4-bis-3,4,5-Trimethoxybenzylidene- dihydrofuran (BTMB), a novel derivative of Taiwanin A, significantly inhibited the proliferation of triple-negative breast cancer (TNBC) cells both in vitro and in vivo. The results show that BTMB inhibited the proliferation of human TNBC cells by the induction of cell-cycle arrest and apoptosis in a dose-dependent fashion. BTMB inhibited the expression of b-catenin, cdc2 and the cell-cycle regulatory proteins, cyclin A, cyclin D1, and cyclin E. The mechanism of action was associated with the suppression of cell survival signaling through inactivation of the Akt and ERK1/2 signaling pathways. Moreover, BTMB induced cell apoptosis through an increase in the expression of BAX, cleaved caspase-3, and cleaved PARP. Moreover, BTMB inhibited TNBC cell colony formation and sensitized TNBC cells to cisplatin, a chemotherapeutic drug. In a TNBC mouse xenograft model, BTMB significantly inhibited the growth of mammary carcinomas through decreased expression of cyclin D1. BTMB was shown to significantly suppress the growth of mammary carcinoma and therefore to have potential as an anticancer therapeutic agent.

Original languageEnglish
Pages (from-to)480-493
Number of pages14
JournalMolecular Cancer Therapeutics
Volume16
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Triple Negative Breast Neoplasms
Cyclin D1
Breast Neoplasms
Apoptosis
Cyclin A
Catenins
Cyclin E
Cell Cycle Proteins
MAP Kinase Signaling System
Mitogen-Activated Protein Kinase Kinases
Growth
Cell Cycle Checkpoints
taiwanin A
Phosphatidylinositol 3-Kinases
Heterografts
Caspase 3
Antineoplastic Agents
Cisplatin
Cell Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dual inhibition of key proliferation signaling pathways in triple-negative breast cancer cells by a novel derivative of Taiwanin A. / Kuo, Yueh Hsiung; Chiang, En Pei Isabel; Chao, Che Yi; Rodriguez, Raymond L.; Chou, Pei Yu; Tsai, Shu Yao; Pai, Man Hui; Tang, Feng Yao.

In: Molecular Cancer Therapeutics, Vol. 16, No. 3, 01.03.2017, p. 480-493.

Research output: Contribution to journalArticle

Kuo, Yueh Hsiung ; Chiang, En Pei Isabel ; Chao, Che Yi ; Rodriguez, Raymond L. ; Chou, Pei Yu ; Tsai, Shu Yao ; Pai, Man Hui ; Tang, Feng Yao. / Dual inhibition of key proliferation signaling pathways in triple-negative breast cancer cells by a novel derivative of Taiwanin A. In: Molecular Cancer Therapeutics. 2017 ; Vol. 16, No. 3. pp. 480-493.
@article{100f1840dc4b4afcad1e2f1bafbf5fb8,
title = "Dual inhibition of key proliferation signaling pathways in triple-negative breast cancer cells by a novel derivative of Taiwanin A",
abstract = "The treatment of breast cancer cells obtained by blocking the aberrant activation of the proliferation signaling pathways PI3K/Akt/mTOR and MEK/ERK has received considerable attention in recent years. Previous studies showed that Taiwanin A inhibited the proliferation of several types of cancer cells. In this study, we report that 3,4-bis-3,4,5-Trimethoxybenzylidene- dihydrofuran (BTMB), a novel derivative of Taiwanin A, significantly inhibited the proliferation of triple-negative breast cancer (TNBC) cells both in vitro and in vivo. The results show that BTMB inhibited the proliferation of human TNBC cells by the induction of cell-cycle arrest and apoptosis in a dose-dependent fashion. BTMB inhibited the expression of b-catenin, cdc2 and the cell-cycle regulatory proteins, cyclin A, cyclin D1, and cyclin E. The mechanism of action was associated with the suppression of cell survival signaling through inactivation of the Akt and ERK1/2 signaling pathways. Moreover, BTMB induced cell apoptosis through an increase in the expression of BAX, cleaved caspase-3, and cleaved PARP. Moreover, BTMB inhibited TNBC cell colony formation and sensitized TNBC cells to cisplatin, a chemotherapeutic drug. In a TNBC mouse xenograft model, BTMB significantly inhibited the growth of mammary carcinomas through decreased expression of cyclin D1. BTMB was shown to significantly suppress the growth of mammary carcinoma and therefore to have potential as an anticancer therapeutic agent.",
author = "Kuo, {Yueh Hsiung} and Chiang, {En Pei Isabel} and Chao, {Che Yi} and Rodriguez, {Raymond L.} and Chou, {Pei Yu} and Tsai, {Shu Yao} and Pai, {Man Hui} and Tang, {Feng Yao}",
year = "2017",
month = "3",
day = "1",
doi = "10.1158/1535-7163.MCT-16-0011",
language = "English",
volume = "16",
pages = "480--493",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Dual inhibition of key proliferation signaling pathways in triple-negative breast cancer cells by a novel derivative of Taiwanin A

AU - Kuo, Yueh Hsiung

AU - Chiang, En Pei Isabel

AU - Chao, Che Yi

AU - Rodriguez, Raymond L.

AU - Chou, Pei Yu

AU - Tsai, Shu Yao

AU - Pai, Man Hui

AU - Tang, Feng Yao

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The treatment of breast cancer cells obtained by blocking the aberrant activation of the proliferation signaling pathways PI3K/Akt/mTOR and MEK/ERK has received considerable attention in recent years. Previous studies showed that Taiwanin A inhibited the proliferation of several types of cancer cells. In this study, we report that 3,4-bis-3,4,5-Trimethoxybenzylidene- dihydrofuran (BTMB), a novel derivative of Taiwanin A, significantly inhibited the proliferation of triple-negative breast cancer (TNBC) cells both in vitro and in vivo. The results show that BTMB inhibited the proliferation of human TNBC cells by the induction of cell-cycle arrest and apoptosis in a dose-dependent fashion. BTMB inhibited the expression of b-catenin, cdc2 and the cell-cycle regulatory proteins, cyclin A, cyclin D1, and cyclin E. The mechanism of action was associated with the suppression of cell survival signaling through inactivation of the Akt and ERK1/2 signaling pathways. Moreover, BTMB induced cell apoptosis through an increase in the expression of BAX, cleaved caspase-3, and cleaved PARP. Moreover, BTMB inhibited TNBC cell colony formation and sensitized TNBC cells to cisplatin, a chemotherapeutic drug. In a TNBC mouse xenograft model, BTMB significantly inhibited the growth of mammary carcinomas through decreased expression of cyclin D1. BTMB was shown to significantly suppress the growth of mammary carcinoma and therefore to have potential as an anticancer therapeutic agent.

AB - The treatment of breast cancer cells obtained by blocking the aberrant activation of the proliferation signaling pathways PI3K/Akt/mTOR and MEK/ERK has received considerable attention in recent years. Previous studies showed that Taiwanin A inhibited the proliferation of several types of cancer cells. In this study, we report that 3,4-bis-3,4,5-Trimethoxybenzylidene- dihydrofuran (BTMB), a novel derivative of Taiwanin A, significantly inhibited the proliferation of triple-negative breast cancer (TNBC) cells both in vitro and in vivo. The results show that BTMB inhibited the proliferation of human TNBC cells by the induction of cell-cycle arrest and apoptosis in a dose-dependent fashion. BTMB inhibited the expression of b-catenin, cdc2 and the cell-cycle regulatory proteins, cyclin A, cyclin D1, and cyclin E. The mechanism of action was associated with the suppression of cell survival signaling through inactivation of the Akt and ERK1/2 signaling pathways. Moreover, BTMB induced cell apoptosis through an increase in the expression of BAX, cleaved caspase-3, and cleaved PARP. Moreover, BTMB inhibited TNBC cell colony formation and sensitized TNBC cells to cisplatin, a chemotherapeutic drug. In a TNBC mouse xenograft model, BTMB significantly inhibited the growth of mammary carcinomas through decreased expression of cyclin D1. BTMB was shown to significantly suppress the growth of mammary carcinoma and therefore to have potential as an anticancer therapeutic agent.

UR - http://www.scopus.com/inward/record.url?scp=85014697615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014697615&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-16-0011

DO - 10.1158/1535-7163.MCT-16-0011

M3 - Article

C2 - 27956520

AN - SCOPUS:85014697615

VL - 16

SP - 480

EP - 493

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -